AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03570008 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 9 days spa residential program
Description: After the inclusion visit, the participants will be involved in a short-term spa residential program of 9 days (Sp). The will be randomized into 3 groups of 30 participants:~* Sp-Ex: spa residential program including physical activity~* Sp-alone: spa residential program alone~* Ex-alone: physical activity alone~After the spa residential program, participants will undergo a one-year at-home follow-up. The participants will be required to complete the same program by themselves.~A journal and an accelerometer-pedometer watch will record the weekly physical activity performed. Monitoring will be further monthly assessed by a health-care professional from the spa resorts.
Study NCT03570008 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 3 sessions of 10 minutes per day of physical exercise
Description: After the inclusion visit, the participants will be involved in a short-term spa residential program of 9 days (Sp). The will be randomized into 3 groups of 30 participants:~* Sp-Ex: spa residential program including physical activity~* Sp-alone: spa residential program alone~* Ex-alone: physical activity alone~After the spa residential program, participants will undergo a one-year at-home follow-up. The participants will be required to complete the same program by themselves.~A journal and an accelerometer-pedometer watch will record the weekly physical activity performed. Monitoring will be further monthly assessed by a health-care professional from the spa resorts.
Study NCT03570008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 sessions of 10 minutes per day of physical exercise
Description: After the inclusion visit, the participants will be involved in a short-term spa residential program of 9 days (Sp). The will be randomized into 3 groups of 30 participants:~* Sp-Ex: spa residential program including physical activity~* Sp-alone: spa residential program alone~* Ex-alone: physical activity alone~After the spa residential program, participants will undergo a one-year at-home follow-up. The participants will be required to complete the same program by themselves.~A journal and an accelerometer-pedometer watch will record the weekly physical activity performed. Monitoring will be further monthly assessed by a health-care professional from the spa resorts.
Study NCT04247568 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Listening to an audiotape
Description: The participants listen to a audiofile that consists of hypnosis
Study NCT04247568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to an audiotape
Description: The participants listen to a audiofile that consists of hypnosis
Study NCT04657367 — intervention group
Intervention type: OTHER
Intervention: Observational study - registry
Description: Observational study - registry
Study NCT02977728 — intervention group
Intervention type: OTHER
Intervention: Olfactory Evaluation
Description: The investigators will evaluate the olfactory system of all participants by the use of the Sniffin'Sticks batterie
Study NCT04691206 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: briefing objectives, intraoperative teaching, and debriefing feedback
Description: A standardized step-wise operative curriculum amongst general surgeons will be implemented among all general surgery residents. Residents will follow and graduate through this curriculum by initiating a perioperative model of briefing objectives, intraoperative teaching, and debriefing feedback (BID).
Study NCT04039321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESPB group
Description: USG probe will be placed in a longitudinal parasagittal orientation 3 cm lateral to T7 spinous process. The erector spinae muscles will be identified hyperechoic transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 21-gauge 10-cm needle was inserted using an in-plane superior-to-inferior approach or an outplane approach. Following confirmation of the correct position of the needle with 5 ml normal saline, a dose of 20 ml %0.25 bupivacaine will be administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine). Standard pain follow up and monitorization will be performed.
Study NCT04039321 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: The patients in this group will be performed no block. Standard pain follow up and monitorization will be performed.
Study NCT01565798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Copper-alloy surfaced patient care objects
Description: Copper-alloy surfaced bed rails, over bed tray tables, chair arms, nurse call devices, laptop and computer monitor bezels, and IV poles were placed into the patient ICU rooms.
Study NCT04587024 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: mHealth intervention
Description: Subjects will receive mHealth direct observation of therapy for 12 weeks
Study NCT04587024 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard of care
Description: Subjects will receive standard of care observation for 12 weeks
Study NCT03832504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: The participant will rest in a seated position.
Study NCT03832504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fan
Description: A fan placed in front of the participant will provide an airflow of 4 m/s throughout the exposure.
Study NCT03832504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Wetting
Description: Tap water (\~18°C) will be applied every 5 minutes to the face, neck, upper and lower arms and upper and lower legs using a spray bottle.
Study NCT03832504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fan + Skin wetting
Description: A fan placed in front of the participant will provide an airflow of 4 m/s throughout the exposure. In addition, tap water (\~18°C) will be applied every 5 minutes to the face, neck, upper and lower arms and upper and lower legs using a spray bottle.
Study NCT00776802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCS-100
Description: GCS-100 80 mg/m2 IV (in the vein) on Study Days 1, 2, 3, 4, and 5 of a 21-day course. Three or up to six patients will be enrolled in each cohort until the maximum tolerated dose is reached. The dose levels: 1) 80 mg/m2; 2) 120 mg/m2; 3) 160 mg/m2
Study NCT04593706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone acetate
Description: the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar
Study NCT04593706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar
Study NCT01300078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF101
Description: MF101 10 g/day MF101 15 g/day
Study NCT04346485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SP TFL RIRS with 145 mcm fiber
Description: retrograde intrarenal surgery
Study NCT04346485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SP TFL RIRS with 200 mcm fiber
Description: retrograde intrarenal surgery
Study NCT04346485 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ho:YAG RIRS with 200 mcm fiber
Description: retrograde intrarenal surgery
Study NCT02828163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Platelet rich plasma
Description: Intralesional injection of 1 milliliter of autologous Platelet rich plasma in the oral erosions every 2 weeks for 3 months.
Study NCT02828163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: 10mg/ml of Triamcinolone acetonide will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
Study NCT00705562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: milk protein formulas, varying carbohydrate/protein sources
Description: ad lib for 0-8 days of age until 28 days of age
Study NCT00776802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide; Dexamethasone
Description: Etoposide 100 mg/m2 on Study Days 3, 4 and 5; Dexamethasone 10 mg/m2 on Study Days 1, 2, 3, 4 and 5.
Study NCT02669134 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Device programming
Description: SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed AV+VV
Study NCT04224220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adult Medical Care Coordination
Description: Nurse-based support that includes a home visit and follow-up coaching telephone calls to monitor patient status and ability to self-manage symptoms.
Study NCT04224220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Patient Monitoring
Description: Nurse-based support and coaching that incorporates the use of technology to monitor patient status and ability to self-manage symptoms.
Study NCT01858623 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Losartan/hydrochlorothiazide
Study NCT01858623 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Losartan
Study NCT01858623 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydrochlorothiazide
Study NCT03555942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follicular phase corifollitropin alfa
Description: GnRH antagonist protocol with corifollitropin alfa initiated in the follicular phase (day 2 or 3 of the menstrual cycle)
Study NCT02669134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Device programming
Description: SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed AV+VV
Study NCT03555942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteal phase corifollitropin alfa
Description: GnRH antagonist protocol with corifollitropin alfa initiated in the luteal phase (5 days after an LH peak)
Study NCT03411798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yisaipu®
Description: Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR \& CRP reduce to normal and BASDAI\<4) maintenance.
Study NCT01402505 — intervention group
Intervention type: PROCEDURE
Intervention: Transvaginal NOTES sleeve gastrectomy
Description: transvaginal NOTES sleeve gastrectomy
Study NCT04523870 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Botanical extract
Description: One capsule
Study NCT04523870 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Main compound of the botanical extract
Description: one capsule
Study NCT04523870 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin, one capsule
Study NCT06731543 — intervention group
Intervention type: OTHER
Intervention: No interventions will be made
Study NCT02209025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Theobromine
Description: Theobromine a compound for cocoa
Study NCT02209025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Study NCT02623842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tonederm® (Radiofrequency non ablative)
Description: The application of RF was performed by physical therapist trained in the technique of radio frequency through the Tonederm® brand device with capacitive transfer method using non-ablative handle with electrode in the region of the external urethral meatro and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration of 20 minutes. The temperature was measured by an infrared thermometer when it reached 41graus radiofrequency was maintained for 2 minutes.
Study NCT04577222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Technical modification during radical prostatectomy
Description: Covering the NVB with fat
Study NCT03913104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Patients will have MifeprexⓇ (mifepristone) shipped to a preferred address via an online mail order pharmacy rather than standard care at clinic visit.
Study NCT04151745 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: external pacemaker switched off
Description: When a hemodynamically stable state is achieved, the external pacemaker will be switched off for 30 minutes. Hemodynamic parameters will be acquired directly prior to switching off, 15 respectively 30 minutes after switching off, and 15 minutes after switching back on. To gain insight in the natural course of stunning, this routine will be repeated the next morning.
Study NCT04332731 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symplicity Spyral™ multi electrode renal denervation system
Description: Symplicity Spyral™ multi-electrode renal denervation catheter (Symplicity Spyral catheter, Medtronic) and associated Symplicity G3™ renal denervation radiofrequency generator (Symplicity G3 generator, Medtronic) will be used in this study. The Symplicity Spyral™ multi-electrode renal denervation catheter is intended to deliver low-level radio frequency (RF) energy through the wall of the renal artery to denervate the human kidney.
Study NCT04332731 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Renal angiogram
Description: Renal angiogram will be used in both treatment and sham groups. Renal angiography is an imaging test used to study the blood vessels in the kidneys. The test will examine the kidney artery anatomy using x-rays following the injection of an x-ray dye (contrast medium). Only patients with eligible renal artery anatomy (between 3 mm and 8 mm) will be randomized ( to treatment or sham groups).
Study NCT04332731 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Renal angiogram
Description: Renal angiogram will be used in both treatment and sham groups. Renal angiography is an imaging test used to study the blood vessels in the kidneys. The test will examine the kidney artery anatomy using x-rays following the injection of an x-ray dye (contrast medium). Only patients with eligible renal artery anatomy (between 3 mm and 8 mm) will be randomized ( to treatment or sham groups).
Study NCT03472313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-958
Description: Healthy Volunteers recruited for the study will undergo a single \[18F\]MNI-958 injection and PET scan.
Study NCT04986943 — intervention group
Intervention type: DEVICE
Intervention: Using ABTHERA Advance without a Wittmann Patch
Description: In this group, patients will be receiving only the ABTHERA Advance product, without the use of the Wittmann Patch
Study NCT03573401 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)
Description: The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.
Study NCT03573401 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Description: The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.
Study NCT01535586 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP versus MAD
Description: Cross over design
Study NCT01285492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 (110 μg indacaterol / 50 μg glycopyrronium o.d.), delivered via Concept1
Study NCT01285492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium (18 μg o.d.), delivered via Handihaler®
Study NCT02785276 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: AutoFuser Pain Pump
Description: Closed loop local anaesthetic infusion system
Study NCT02785276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoFuser Pain Pump
Description: Closed loop local anaesthetic infusion system
Study NCT02785276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Commonly used local anaesthetic drug
Study NCT02785276 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (0.9%)
Description: Normal saline is a sterile, non-pyrogenic solution for fluid and electrolyte replenishment for intravenous administration. This will be the solution used for the intraperitoneal infusion in the placebo/control group.
Study NCT00840671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
Study NCT00840671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline Solution
Description: 0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
Study NCT00634920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus (Certican®) tablets administered orally in two divided doses (b.i.d.) at a starting dose of 4 mg/day adjusted to target a trough blood concentration between 6 and 10 ng/mL in period 2.
Study NCT00634920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine A
Description: CsA (Sandimmun Neoral), based on C0-h levels 75-200 ng/mL or C2-h levels 700 900 ng/mL from randomization to Month 6, or C0-h levels 50-150 ng/mL or C2-h levels 600 800 ng/mL from Month 6 to Month 36, according to local method
Study NCT00634920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric Coated Mycophenolate Sodium (EC-MPS)
Description: Target dose 1440 mg in the control group, target dose 1080 in the everolimus group (higher dose in the CsA group because of interactions of CsA on gastric reabsorption of mycophenolate)
Study NCT00634920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric Coated Mycophenolate Sodium (EC-MPS)
Description: Target dose 1440 mg in the control group, target dose 1080 in the everolimus group (higher dose in the CsA group because of interactions of CsA on gastric reabsorption of mycophenolate)
Study NCT00634920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: For both groups: minimum corticosteroid dose of 10 mg until week 12, 5-10 mg until month 12, month 12-36 corticosteroid treatment on investigator's descretion.
Study NCT00634920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: For both groups: minimum corticosteroid dose of 10 mg until week 12, 5-10 mg until month 12, month 12-36 corticosteroid treatment on investigator's descretion.
Study NCT00634920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Induction therapy 20 mg basiliximab on Day 0 prior to reperfusion and 20 mg on Day 4 post-TX.
Study NCT00634920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Induction therapy 20 mg basiliximab on Day 0 prior to reperfusion and 20 mg on Day 4 post-TX.
Study NCT03181906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-Consultation Medication Reconciliation
Description: Medication reconciliation service to be done for participants randomised to the intervention group
Study NCT04260399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender Aromatherapy
Description: Participants in the experimental group will be passively exposed to lavender essential oil
Study NCT04260399 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Aromatherapy
Description: Participants in the control group will be passively exposed to saline water aromatherapy
Study NCT04353817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination tablet for oral administration qd in the morning.
Study NCT04353817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration qd in the evening.